{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-049879","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2021-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.211124+00:00","generated_at":"2026-06-28T23:20:10.408748+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"KalVista stockholders elect three Class III directors at 2021 annual meeting","bullets":["Elected Albert Cha, Martin Edwards, and Nancy Stuart as Class III directors for three-year terms expiring 2024.","Ratified Deloitte & Touche as independent auditor for fiscal year ending April 30, 2022: 22.6M for, 13.6K against.","Approved non-binding advisory vote on named executive officer compensation: 19.7M for, 2.5M against.","All proposals passed; broker non-votes were 464,900 on director elections and compensation vote."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-049879","json":"https://secwatch.observer/filing/0001564590-21-049879.json","markdown":"https://secwatch.observer/filing/0001564590-21-049879.md","text":"https://secwatch.observer/filing/0001564590-21-049879.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000156459021049879/0001564590-21-049879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000156459021049879/kalv-8k_20210930.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T23:20:10.408748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}